Kite Pharma Overview
- Founded
- 2009
- Status
- Acquired/Merged
- Employees
- 200
- Latest Deal Type
- M&A
- Latest Deal Amount
- $12B
Kite Pharma General Information
Description
Developer of active immunotherapies for cancer intended to cure cancer. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. It's dual platform has the potential to change the paradigm of cancer therapy and address both hematological and solid tumor cancers.
Contact Information
Website
www.kitepharma.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Primary Office
- 2400 Broadway
- Santa Monica, CA 90404
- United States
+1 (310) 000-0000
Kite Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 03-Oct-2017 | $12B | 00000 | 0000 | Completed | Profitable |
| 4. Secondary Transaction - Open Market | 01-Apr-2015 | 00000 | Completed | Generating Revenue | ||
| 3. IPO | 20-Jun-2014 | 00000 | 00000 | 00000 | Completed | Generating Revenue |
| 2. Mezzanine | 28-Apr-2014 | $50M | $85M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | 15-May-2013 | $35M | $35M | 00000 | Completed | Clinical Trials - Phase 2 |
Kite Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Kite Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of active immunotherapies for cancer intended to cure cancer. The company is engaged in developing engineered
Biotechnology
Santa Monica, CA
200
As of 2022
00000
000
0000-00-00
000000&0
00000
00000000
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris n
0000000000000
Vancouver, Canada
000
As of 0000
00000
0000
0000-00-00
000000000000
000000
prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000000
Utrecht, Netherlands
00
As of 0000
00.000
0000000000 0
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialKite Pharma Competitors (36)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zymeworks | Formerly VC-backed | Vancouver, Canada | 000 | 00000 | 000000000000 | |
| 000000 | Venture Capital-Backed | Utrecht, Netherlands | 00 | 00.000 | 0000000000 0 | 00.000 |
| 0000000 0000000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
Kite Pharma Patents
Kite Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210161959-A1 | Chimeric antigen receptor t cell therapy | Pending | 06-Nov-2019 | 0000000000 | |
| US-20200397823-A1 | Tgf-beta receptors and methods of use | Pending | 21-Jun-2019 | 0000000000 | |
| AU-2020267378-A1 | Methods of administering chimeric antigen receptor immunotherapy | Pending | 03-May-2019 | 000000000 | |
| CA-3138707-A1 | Methods of administering chimeric antigen receptor immunotherapy | Pending | 03-May-2019 | 000000000 | |
| US-20200384027-A1 | Methods of administering chimeric antigen receptor immunotherapy | Pending | 03-May-2019 | A61K35/17 |
Kite Pharma Executive Team (23)
Kite Pharma Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christi Shaw | Self | Chief Executive Officer & Board Member | 000 0000 |
| Roy Doumani | Kite Pharma | Independent Director | 000 0000 |
Kite Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialKite Pharma Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Arie Belldegrun | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| BB Biotech | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Bellco Capital | Family Office | Minority | 000 0000 | 000000 0 | |
| Commercial Street Capital | Venture Capital | Minority | 000 0000 | 000000 0 |
Kite Pharma Investments & Acquisitions (9)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 000 | 02-Nov-2021 | 00000 0000 | 00000 | Drug Discovery | |
| 0000 00000000 | 24-Feb-2021 | 00000 0000 | 0000 | Drug Delivery | 000000000 |
| 000000000 000 | 16-Feb-2021 | 00000 0000 | 0000 | Drug Discovery | |
| 0000000 00000 | 28-Aug-2019 | 00000 0000 | 0000 | Drug Discovery | |
| Gadeta | 19-Jul-2018 | Early Stage VC | Biotechnology |